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Background: Andhra Pradesh state has the highest HIV burden
in India. Andhra PradeshAIDSConsortium (APAIDSCON) the largest
public health partnership a network of 20 medical colleges estab-
lished to address HIV AIDS in India was spearheaded by SHARE
India and funded in part by United States Centers for Disease Con-
trol & Prevention Cooperative agreement # U62/CCU025160-02.
2005 –2010
Methods&Materials: Results of Interventions to reduce stigma
and discrimination were analyzed. Both quantitative and quali-
tative methods were used. Adapted questionnaire on stigma and
discrimination was used. Methods included In Depth Interviews
with key stakeholders and patients to understand reporting of
Stigma & Discrimination. Focus Group Discussions were used.
Ethics committee approval was obtained.
Results: The qualitative data indicated that stigma and discrim-
ination present in the consortiumamongHealth Care Providers due
to the “fear element” was substantially decreased due to measures
taken by the project like training and sensitization programs for
HCPs, guidelines and protocol implementation to reduce stigma
and discrimination, prevention of segregation i.e. separate bed
or special identiﬁcation marks during admission, staff compensa-
tion and facilitation of universal precautions. The qualitative data
demonstrated that management of the sampled private hospitals
never placed hurdles to admitting HIV positive cases. This created a
conducive environment against stigmaanddiscrimination. Instruc-
tionswere givennot tomentionHIVpositive status in patient’s case
record. Segregation of HIV positive patients for routine care was
eliminated. After conclusion of the project follow up interviews
of 117 in-patients from four of the sampled institutes demon-
strated persistence of best practices with more than 96% of the
PLHIV responding that there is no differential treatment or denial
of treatment in these sites.
Conclusion: Across the APAIDSCON consortium persistent
efforts to remove the knowledge barriers had a salutary effect; HIV
services could be provided without stigma and discrimination in
the private sector. Grounded efforts with the managements both
in private and public sector yield sustained results long after the
intervention ended.
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Background: Analysis of micro RNA(miRNAs) based regulatory
networks in infectious diseases is a challenging task in the era of
post genomics and prediction of the miRNAs associated with phar-
macogenomics of acquired Immune Deﬁciency Syndrome (AIDS) is
an initiation towards the miRNA based therapy for AIDS.
Methods & Materials: Initially we have taken the list of human
genes associated with AIDS from PharmG-KB and further we have
analyzed the network of humanmiRNAswhich are associatedwith
AIDS related genes from EnrichR. Finally we performed statistical
analysis like P value, Z test and combined score of Students T test
andANNOVA to analyze the signiﬁcance of those predictedmiRNAs
towards the Human Immune Virus (HIV) related genes.
Results: PharmGKB contains 6 genes (ABCB1, CYCSP5, G6PD,
GSTM1, NAT2 and NR1I2) which are associated with the Pharma-
cogenomicsofAIDS. EnrichRhaspredicted6miRNAs (hsa-miR-18a,
hsa-miR-1, hsa-miR-206, hsa-miR-24, hsa-miR-125a and hsa-miR-
125b) which are related to AIDS related genes. Based on the
statistical analysis, it has been found that hsa-miR-18a has a mini-
mumPvalue and Z score of 0.0370& -1.82 respectively. Association
of hsa-miR-18a with HIV related genes shows a 4 fold increase
when compared with hsa-miR-1 and hsa-miR-206. Similarly the
association of hsa-miR-24 shows a 3 fold decrease when compared
withhsa-miR-18a andﬁnally, hsa-miR-125a andhsa-miR-125bhas
a 5 fold decrease when compared with hsa-miR-18a.
Conclusion: Based on the statistical analysis of gene andmiRNA
regulated networks, it was found that hsa-miR-18a show a good
statistical signiﬁcance towards genes which are related to AIDS
and in future, hsa-miR-18a may turn out to be a potential target
for the miRNA based therapeutics of AIDS. At present, we have
applied the above mentioned methodology for AIDS and in future,
this methodology will also be applied to other infectious diseases.
http://dx.doi.org/10.1016/j.ijid.2016.02.564
